Rituximab: clinical development and future directions

被引:24
作者
Cheson, BD [1 ]
机构
[1] NCI, Bethesda, MD 20892 USA
关键词
antibody; CD20; CLL lymphoma; monoclonal; rituximab;
D O I
10.1517/14712598.2.1.97
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
The availability of effective monoclonal antibodies (mAbs) has revolutionised the management of patients with B-cell malignancies. The most widely studied of these agents is rituximab (Rituxan(TM), IDEC Pharmaceuticals, San Diego, CA), a chimeric anti-CD20 antibody. Using the standard 4-weekly administration schedule, rituximab induces responses in almost half of patients with relapsed follicular/low-grade (F/LG) non-Hodgkin's lymphoma (NHL) with complete remissions in 6%. Lower response rates (RRs) have been noted in chronic lymphocytic leukaemia (CLL) using the standard dose and schedule. The drug has been well tolerated in most patients with common adverse events including mild to moderate fevers and chills and rare occurrences of a serious syndrome related to cytokine release and rapid tumour clearance. This antibody is also active against aggressive NHL, mantle cell NHL, post-transplant lymphoproliferative disorder (PTLD), lymphoplasmacytic NHL and hairy cell leukaemia and is also being evaluated in autoimmune disorders. Combinations of rituximab with chemotherapy regimens such as CHOP (cyclophosphamide, adriamycin, vincristine, predinisone) may alter the therapeutic paradigm for these diseases. The future promise of this antibody is a foundation on which to develop new strategies to increase the cure of patients with lymphoid malignancies.
引用
收藏
页码:97 / 110
页数:14
相关论文
共 108 条
[61]  
Lucas JB, 2000, BLOOD, V96, p831A
[62]   IDEC-C2B8: Results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma [J].
Maloney, DG ;
GrilloLopez, AJ ;
Bodkin, DJ ;
White, CA ;
Liles, TM ;
Royston, I ;
Varns, C ;
Rosenberg, J ;
Levy, R .
JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (10) :3266-3274
[63]  
MALONEY DG, 1994, BLOOD, V84, P2457
[64]  
Maloney DG, 1997, BLOOD, V90, P2188
[65]   Rituximab chimeric Anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma:: Half of patients respond to a four-dose treatment program [J].
McLaughlin, P ;
Grillo-López, AJ ;
Link, BK ;
Levy, R ;
Czuczman, MS ;
Williams, ME ;
Heyman, MR ;
Bence-Bruckler, I ;
White, CA ;
Cabanillas, F ;
Jain, V ;
Ho, AD ;
Lister, J ;
Wey, K ;
Shen, D ;
Dallaire, BK .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (08) :2825-2833
[66]   Fludarabine, mitoxantrone, and dexamethasone: An effective new regimen for indolent lymphoma [J].
McLaughlin, P ;
Hagemeister, FB ;
Romaguera, JE ;
Sarris, AH ;
Pate, O ;
Younes, A ;
Swan, F ;
Keating, M ;
Cabanillas, F .
JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (04) :1262-1268
[67]   Peripheral T-cell lymphoma following Rituximab therapy for B-cell lymphoma [J].
Micallef, INM ;
Kirk, A ;
Norton, A ;
Foran, JM ;
Rohatiner, AZS ;
Lister, TA .
BLOOD, 1999, 93 (07) :2427-2428
[68]   TREATMENT OF B-CELL LYMPHOMA WITH MONOCLONAL ANTI-IDIOTYPE ANTIBODY [J].
MILLER, RA ;
MALONEY, DG ;
WARNKE, R ;
LEVY, R .
NEW ENGLAND JOURNAL OF MEDICINE, 1982, 306 (09) :517-522
[69]   Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: A retrospective analysis on 32 patients [J].
Milpied, N ;
Vasseur, B ;
Parquet, N ;
Garnier, JL ;
Antoine, C ;
Quartier, P ;
Carret, AS ;
Bouscary, D ;
Faye, A ;
Bourbigot, B ;
Reguerre, Y ;
Stoppa, AM ;
Bourquard, P ;
de Ligny, BH ;
Dubief, F ;
Mathieu-Boue, A ;
Leblond, V .
ANNALS OF ONCOLOGY, 2000, 11 :113-116
[70]   IDEC-C2B8 anti-CD20 (Rituximab) immunotherapy in patients with low-grade non-Hodgkin's lymphoma and lymphoproliferative disorders: evaluation of response on 48 patients [J].
Nguyen, DT ;
Amess, JA ;
Doughty, H ;
Hendry, L ;
Diamond, LW .
EUROPEAN JOURNAL OF HAEMATOLOGY, 1999, 62 (02) :76-82